ArticleAmerican journal of cancer research2026
Restoring osimertinib sensitivity in EGFR-mutant NSCLC: the role of anlotinib in modulating Wnt/β-catenin/YAP pathways.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the role of anlotinib in restoring osimertinib sensitivity in EGFR-mutant non-small cell lung cancer (NSCLC) by targeting the Wnt/β-catenin/YAP signaling and PD-L1 expression. Using osimertinib-resistant HCC827 cells with high PD-L1 expression, a stable PD-L1 knockdown line (Sh-PD-L1) was generated through lentiviral vectors. Resistance was induced by stepwise exposure to osimertinib, and the two constructed resistant cell lines were named OR (osimertinib-resistant) and Sh-PD-L1-OR (PD-L1 knockdown osimertinib-resistant) cell lines. Functional assays, including wound healing, Transwell, and MTT, along with Western blot analysis, were conducted in both cell and animal models. Sh-PD-L1 significantly reduced PD-L1 and EGFR expression (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.